aTyr Pharma (LIFE) Misses Q1 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update
May 13, 2021 4:05 PM EDTData from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter.
Preclinical data for IND candidate ATYR2810 showed anti-tumor effects in models of TNBC and NSCLC.
Bispecific antibody project with subsidiary Pangu BioPharma achieved milestones for first of two-year project.
Ended the quarter with $50.6 million in cash, cash equivalents and investments.
Company to host conference call and webcast today, May 13, at 5:00 p.m. EDT / 2:00 p.m. PDT.
SAN DIEGO, May 13,... More
